CD66a (CEACAM1) is the only CD66 variant expressed on the surface of plasma cells in multiple myeloma: a refined target for radiotherapy trials?
- 17 May 2010
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 149 (5) , 795-796
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Radioimmunotherapy-Based Conditioning Regimens for Stem Cell TransplantationSeminars in Hematology, 2008
- Differential expression of the carcinoembryonic antigen-related cell adhesion molecules panCD66, CD66a, CD66c and of sialyl-Lewis x (CD15s) on blast cells of acute leukemiasInternational Journal of Hematology, 2008
- High expression of CEACAM6 and CEACAM8 mRNA in acute lymphoblastic leukemiasAnnals of Hematology, 2007
- The expression of CD66a and possible roles in colorectal adenoma and adenocarcinomaInternational Journal of Colorectal Disease, 2006
- Targeted radiotherapy in the conditioning prior to haematopoietic stem cell transplantation: Results of a phase I trial using an yttrium-90-labelled anti-CD66 murine monoclonal antibody demonstrating consistently high BM uptakeTransplantation and Cellular Therapy, 2006
- CD66 Expression on Malignant and Normal Plasma Cells: A Potential Target for Therapy.Blood, 2005
- 188Re or 90Y‐labelled anti‐CD66 antibody as part of a dose‐reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I–II studyBritish Journal of Haematology, 2005
- Adhesion of Neutrophils to Fibronectin: Role of the CD66 AntigensCellular Immunology, 2001
- Tumor-suppressive activity of CD66a in prostate cancerCancer Gene Therapy, 1999
- The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissuesSeminars in Cancer Biology, 1999